台股 » 個股 » 易威 » 籌碼相關 » 券商分點績效 » 券商分點個股進出

易威

(1799)
  • 股價
    66.6
  • 漲跌
    ▼7.4
  • 漲幅
    -10.00%
  • 成交量
    1,949
  • 產業
    上櫃 生技醫療類股
  • 68人加入追蹤

    立即追蹤

  • 本地時間:14:30(已收盤)

     
易威 (1799)籌碼相關-安泰-大發 券商分點個股進出
券商分點績效/獲利分析

透過統計各券商分點在長期買賣某個股的操作績效,來找出真正獲利的贏家所在券商分點,進而追蹤此贏家所操作的股票與軌跡。

安泰-大發 券商分點個股進出

日期買進張數買進均價賣出張數賣出均價收盤價買賣超60日均量成交佔比 大量交易提示
2024/12/23166.30166.4066.4006800.00%
2024/12/13155.0000.0054.9016780.15%
2024/11/15172.0000.0066.0016780.15%
2024/11/13264.0000.0064.0026520.31%
2024/10/0800.003123.83126.00-3839-0.36%
2024/10/072108.5000.00116.5028300.24%
2024/10/0100.00399.8097.20-3787-0.38%
2024/09/3000.007108.50108.00-7777-0.90%
2024/09/263136.3300.00133.0037850.38%
2024/09/251148.5000.00147.5017840.13%
2024/09/241161.002161.50159.00-1789-0.13%
2024/09/235157.4000.00158.0057940.63%
2024/09/2000.001171.00169.00-1782-0.13%
2024/09/192170.5000.00177.0027850.25%
2024/09/162176.0000.00175.5027800.26%
2024/09/102188.5000.00183.0028120.25%
2024/07/091138.0000.00139.0014990.20%
2024/06/2700.0012114.17118.50-12393-3.05%
2024/06/2600.0015107.33108.00-15378-3.97%
2024/06/2000.004104.00105.00-4372-1.08%
2024/06/192104.5000.00101.5023740.53%
2024/06/13196.0000.0096.0013290.30%
2024/05/30591.9200.0090.9053201.56%
2024/05/291095.5000.0094.50103193.13%
2024/05/281199.0100.00100.00113123.52%
2024/05/27297.8000.00100.0023070.65%
2024/05/1300.00375.0074.00-3258-1.16%
2024/05/1000.00577.0476.50-5258-1.93%
2024/05/0700.00375.0075.00-3267-1.12%
2024/05/0600.00173.5073.50-1265-0.38%
2024/04/2300.001168.1368.00-11256-4.29%
2024/03/1100.000.261.4061.40-0.2218-0.07%
2024/03/08362.2000.0061.0032141.40%
2024/03/05963.0000.0064.0092004.49%
2024/03/011153.5900.0054.80111835.99%
2024/02/2000.005550.5448.30-55180-30.42%
2024/02/16852.7800.0052.0081834.36%
2024/02/152754.970.755.0055.5026.317714.79%
2024/02/051649.7800.0050.50161649.73%
2024/01/23240.0000.0039.9521481.35%
2024/01/16141.1000.0041.1511850.54%
2024/01/12139.7500.0040.5511930.52%
易威慢性心臟衰竭用藥獲中國藥證 明年Q1底展開銷售Anue鉅亨-2023/10/30
美新行政令強化製藥在地化 易威、泰福-KY迎來新訂單Anue鉅亨-2022/09/20
〈易威法說〉策略轉型見成效 新藥、學名藥營收比重拚達7成Anue鉅亨-2021/12/17
易威 相關文章
易威 相關影音